Ra Medical Systems reports Q3 2022 loss, no revenue; merger with Catheter Precision progressing

Catheter Precision, Inc.

2022-Q3 EPS reported -$28.00 revenue$14,000

Q3 2022 revenue $0; loss from continuing ops $4.8M ($4.36/share) vs $7.4M loss in Q3 2021.
Adjusted EBITDA negative $4.1M, improved from negative $6.9M in Q3 2021.
Cash and equivalents $13.7M at Sept 30; raised ~$4.9M after quarter via ATM.
Proposed reverse merger with Catheter Precision on track for late 2022/early 2023; Catheter stakeholders to own ~80%.
Effected 1-for-50 reverse stock split on Oct 3 to maintain NYSE American listing.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Catheter Precision, Inc. reported financial results for the nine months ended September 30, 2022.

Period: the nine months ended September 30, 2022
Result: reported results

Exact text from the filing

On November 14, 2022, Ra Medical Systems, Inc. (the “Company”) issued a press release announcing its financial results for the three and nine months ended September 30, 2022.

View on SEC.gov

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Catheter Precision, Inc. reported financial results for the three months ended September 30, 2022.

Period: the three months ended September 30, 2022
Result: reported results

Exact text from the filing

On November 14, 2022, Ra Medical Systems, Inc. (the “Company”) issued a press release announcing its financial results for the three and nine months ended September 30, 2022.

View on SEC.gov

44 earnings releases filed in the last 30 days. Browse all earnings releases →

Catheter Precision, Inc. filing history →

Source: SEC EDGAR

accession 0001564590-22-037674

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.